Wisp expands into migraine care, offering asynchronous consults and medication access
New offering combines online consultations, prescription medication delivery, and ongoing follow-up
Wisp, the U.S.’s largest women-focused telehealth platform, has launched a new migraine care vertical — expanding its clinical services beyond reproductive and hormonal health into one of the most under-treated areas in women’s healthcare.
The new offering combines online consultations, prescription medication delivery, and ongoing follow-up to help women manage and prevent migraines without the long waits or high costs of traditional neurology care. Patients can now access a certified migraine specialist within 72 hours — a significant improvement on the national average of 34 days, which in some areas stretches beyond 90.
Closing the gap in migraine treatment
Migraines affect around one in five women and occur nearly three times as often in women as in men. While both men and women experience migraines, women report longer attack duration, greater disability, higher recurrence rates, and slower recovery.
The report also underscores the hormonal dimension: menstrual migraine - occurring within two days before and three days after menstruation - has been strongly linked to PMS and is a leading cause of debilitating symptoms for many women. Despite this, research into sex-specific differences in migraine remains limited, even as women are much more likely to experience them than men. McKinsey’s 2024 ‘Closing the women’s health gap’ report estimated that addressing this gap could yield 2.7 million annual DALYs and an $80 billion gain in global GDP.
“Migraine care is the natural next step for Wisp,” said Monica Cepak, CEO of Wisp.
“Only one in four adults with episodic migraines receive diagnosis and treatment, and our patients continue to ask for options. We’re delivering on our promise to democratize access to care, breaking down barriers so women can enjoy more pain-free days without the long wait times or high costs.”
How Wisp’s migraine model works
Patients begin with a $60 asynchronous consult, completing a brief intake form and uploading short videos that help clinicians assess symptoms and eligibility. A licensed provider — certified by the National Headache Foundation — reviews each case and creates a personalized treatment plan.
The model allows Wisp to provide a tailored mix of immediate-relief, anti-nausea, and preventive medications. Common acute treatments include Imitrex (Sumatriptan), Maxalt (Rizatriptan), and Zomig ODT (Zolmitriptan); anti-nausea options such as Zofran ODT (Ondansetron) and Reglan (Metoclopramide) are available for patients with associated symptoms.
For those requiring preventive therapy, Wisp’s clinicians can prescribe longer-term medications such as Topamax (Topiramate), Toprol XL (Metoprolol XL), or antidepressant-based options including Elavil (Amitriptyline), Lexapro (Escitalopram), Paxil (Paroxetine), and Effexor ER (Venlafaxine ER).
Patients check in every six weeks until a stable treatment plan is reached, after which quarterly follow-ups at $30 maintain ongoing monitoring and prescription renewals. All prescriptions are sent the same day to the patient’s local pharmacy — no insurance required.
“Migraines can be incredibly disruptive, but they’re also highly manageable with the right treatment plan,” said Dr. Jennifer Peña, Chief Medical Officer at Wisp.
“Our approach gives patients timely access to providers, tailored treatment options, and continuous support so they feel empowered to take control of their health.”
Why it matters
For many women, migraine care falls between the cracks of primary and specialist medicine. Access to neurologists is limited, and hormonal factors often go underexamined. Wisp’s asynchronous approach — where patients upload videos and complete digital assessments rather than schedule live calls — opens doors for those who might otherwise delay care due to cost, time, or stigma.
Wisp’s expansion into migraine management is also another example of women’s health moving beyond reproductive health and fertility - and an area with a huge potential for impact.